tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Scorpion Stings D065008 1 associated lipids
Drug-Related Side Effects and Adverse Reactions D064420 3 associated lipids
Retrognathia D063173 1 associated lipids
End Stage Liver Disease D058625 1 associated lipids
Candidiasis, Invasive D058365 2 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Thrombotic Microangiopathies D057049 1 associated lipids
Central Serous Chorioretinopathy D056833 1 associated lipids
Leukoencephalopathies D056784 3 associated lipids
Netherton Syndrome D056770 1 associated lipids
Latent Tuberculosis D055985 1 associated lipids
Invasive Pulmonary Aspergillosis D055744 1 associated lipids
Keratosis, Actinic D055623 3 associated lipids
Multiple Pulmonary Nodules D055613 2 associated lipids
Pancreatitis, Graft D055589 1 associated lipids
Failed Back Surgery Syndrome D055111 3 associated lipids
Primary Graft Dysfunction D055031 1 associated lipids
Idiopathic Interstitial Pneumonias D054988 1 associated lipids
Dendritic Cell Sarcoma, Interdigitating D054739 1 associated lipids
Precursor Cell Lymphoblastic Leukemia-Lymphoma D054198 10 associated lipids
Posterior Leukoencephalopathy Syndrome D054038 1 associated lipids
Dysuria D053159 1 associated lipids
Nocturia D053158 1 associated lipids
Delayed Graft Function D051799 2 associated lipids
Renal Insufficiency D051437 8 associated lipids
Lymphohistiocytosis, Hemophagocytic D051359 1 associated lipids
Granulomatosis, Orofacial D051261 2 associated lipids
Atherosclerosis D050197 85 associated lipids
Dyslipidemias D050171 7 associated lipids
Diabetes Complications D048909 4 associated lipids
Hepatic Insufficiency D048550 1 associated lipids
Colitis, Collagenous D046729 1 associated lipids
Protoporphyria, Erythropoietic D046351 1 associated lipids
Coproporphyria, Hereditary D046349 1 associated lipids
Ileus D045823 3 associated lipids
Intestinal Volvulus D045822 1 associated lipids
Cholecystolithiasis D041761 2 associated lipids
Mastocytosis, Cutaneous D034701 1 associated lipids
Hypoalbuminemia D034141 1 associated lipids
Hyperuricemia D033461 4 associated lipids
Papillomavirus Infections D030361 4 associated lipids
Denys-Drash Syndrome D030321 1 associated lipids
Pulmonary Disease, Chronic Obstructive D029424 16 associated lipids
Polyomavirus Infections D027601 1 associated lipids
Coronary Stenosis D023921 6 associated lipids
Lacerations D022125 1 associated lipids
Brachial Plexus Neuritis D020968 2 associated lipids
Neuroaspergillosis D020953 2 associated lipids
Hypoxia-Ischemia, Brain D020925 22 associated lipids
Central Nervous System Viral Diseases D020805 1 associated lipids
Intracranial Thrombosis D020767 2 associated lipids
Parkinsonian Disorders D020734 20 associated lipids
Nervous System Autoimmune Disease, Experimental D020721 3 associated lipids
Stroke D020521 32 associated lipids
Brain Infarction D020520 17 associated lipids
Peroneal Neuropathies D020427 1 associated lipids
Sciatic Neuropathy D020426 13 associated lipids
Osteoarthritis, Knee D020370 13 associated lipids
Paraneoplastic Syndromes, Nervous System D020361 1 associated lipids
Hypertensive Encephalopathy D020343 1 associated lipids
Migraine with Aura D020325 1 associated lipids
Autoimmune Diseases of the Nervous System D020274 1 associated lipids
Neurotoxicity Syndromes D020258 34 associated lipids
Ventricular Remodeling D020257 28 associated lipids
Infarction, Middle Cerebral Artery D020244 35 associated lipids
Optic Nerve Injuries D020221 4 associated lipids
Facial Nerve Injuries D020220 1 associated lipids
Trauma, Nervous System D020196 2 associated lipids
Nocturnal Myoclonus Syndrome D020189 1 associated lipids
Sleep Apnea, Central D020182 1 associated lipids
Citrullinemia D020159 1 associated lipids
Hepatopulmonary Syndrome D020065 1 associated lipids
Epstein-Barr Virus Infections D020031 3 associated lipids
Genetic Predisposition to Disease D020022 24 associated lipids
Miller Fisher Syndrome D019846 1 associated lipids
Hepatitis C, Chronic D019698 12 associated lipids
Hepatitis B, Chronic D019694 4 associated lipids
Hepatitis, Autoimmune D019693 1 associated lipids
Neurodegenerative Diseases D019636 32 associated lipids
Intracranial Hypertension D019586 4 associated lipids
Dermatitis, Perioral D019557 4 associated lipids
Pouchitis D019449 3 associated lipids
Endotoxemia D019446 27 associated lipids
Oral Ulcer D019226 1 associated lipids
Gingival Overgrowth D019214 7 associated lipids
Fasciitis, Necrotizing D019115 1 associated lipids
Postoperative Hemorrhage D019106 7 associated lipids
Multiple Endocrine Neoplasia Type 2a D018813 1 associated lipids
Anemia, Iron-Deficiency D018798 6 associated lipids
Encephalitis, Viral D018792 3 associated lipids
Hypoplastic Left Heart Syndrome D018636 1 associated lipids
Cryptogenic Organizing Pneumonia D018549 3 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Lichen Sclerosus et Atrophicus D018459 2 associated lipids
Vasculitis, Leukocytoclastic, Cutaneous D018366 5 associated lipids
Hutchinson's Melanotic Freckle D018327 2 associated lipids
Angiofibroma D018322 2 associated lipids
Cervical Intraepithelial Neoplasia D018290 1 associated lipids
Seminoma D018239 2 associated lipids
Smooth Muscle Tumor D018235 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Gaweco AS et al. Distinct intragraft cytokine gene expression patterns during acute hepatic rejection under cyclosporine versus FK 506 primary immunosuppression. 1994 Transplant. Proc. pmid:7527948
Mathieu C et al. Potential role of 1,25(OH)2 vitamin D3 as a dose-reducing agent for cyclosporine and FK 506. 1994 Transplant. Proc. pmid:7527950
Piekoszewski W et al. Pharmacokinetic and pharmacodynamic effects of coadministration of methylprednisolone and tacrolimus in rabbits. 1994 J. Pharmacol. Exp. Ther. pmid:7513355
Mueller AR et al. Severe neurotoxicity after liver transplantation: association between FK 506 therapy and hepatitis C virus disease. 1994 Transplant. Proc. pmid:7527951
Ueki M et al. Peritoneal-omental pouch as a site for islet allotransplantation. 1994 Transplant. Proc. pmid:7513462
Platz KP et al. Causes of death following liver transplantation in FK 506- and cyclosporine-treated patients. 1994 Transplant. Proc. pmid:7527952
Yasunami Y et al. Acceptance of donor-specific islet allografts in rat by intraportal preimmunization with islets and FK 506. 1994 Transplant. Proc. pmid:7513467
Christe W Neurological disorders in liver and kidney transplant recipients. 1994 Transplant. Proc. pmid:7527953
Ueki M et al. Functional and morphologic characterization of renal subcapsular islet isografts in rats treated with FK 506. 1994 Transplant. Proc. pmid:7513469
Tze WJ et al. Immunohistochemical studies of pig islet xenograft in rats immunosuppressed with FK 506. 1994 Transplant. Proc. pmid:7513470
Tze WJ et al. Prolongation of pig islet xenograft survival in rats by local immunosuppression with FK 506. 1994 Transplant. Proc. pmid:7513471
Fukuzaki T et al. Nonvascularized islet xenograft rejection in a mouse-to-rat combination where the vascularized heart is rapidly rejected. 1994 Transplant. Proc. pmid:7513472
Ohtsuka S et al. Hamster-to-rat xenotransplantation of whole pancreas by FK 506 combined with splenectomy. 1994 Transplant. Proc. pmid:7513473
Hachida M et al. [The rescue effect of FK506 in refractory rejection after cardiac transplantation]. 1994 Nihon Kyobu Geka Gakkai Zasshi pmid:7528255
Sugiyama E et al. FK506, an immunosuppressant, partially inhibits interleukin 6 production by adherent rheumatoid synovial cells. 1994 J. Rheumatol. pmid:7528280
Bennett WM et al. Nephrotoxicity of immunosuppressive drugs. 1994 Nephrol. Dial. Transplant. pmid:7528363
Bennett WM et al. Nephrotoxicity of immunosuppressive drugs. 1994 Miner Electrolyte Metab pmid:7531274
McCashland TM et al. Bile acid metabolism and biliary secretion in patients receiving orthotopic liver transplants: differing effects of cyclosporine and FK 506. 1994 Hepatology pmid:7514561
Husi H et al. Mapping of the immunophilin-immunosuppressant site of interaction on calcineurin. 1994 J. Biol. Chem. pmid:7514602
Moudgil A et al. Inhibition of in vitro immunoglobulin production by a novel immunosuppressive drug brequinar sodium. 1994 Transplant Sci pmid:7528627
Sekigawa I et al. FK506 can inhibit apoptotic cell death induced by the HIV-1 envelope glycoprotein gp120. 1994 AIDS pmid:7531458
Mazariegos GV et al. Rubella infection after orthotopic liver transplantation. 1994 Pediatr. Infect. Dis. J. pmid:7514783
Klaus GG et al. Properties of mouse CD40. Ligation of CD40 activates B cells via a Ca(++)-dependent, FK506-sensitive pathway. 1994 Eur. J. Immunol. pmid:7528676
Mañez R et al. Fluconazole therapy in transplant recipients receiving FK506. 1994 Transplantation pmid:7515201
Tzakis AG et al. Intestinal transplantation. 1994 Annu. Rev. Med. pmid:7515221
Foster CA et al. Pharmacological modulation of endothelial cell-associated adhesion molecule expression: implications for future treatment of dermatological diseases. 1994 J. Dermatol. pmid:7531725
Mulkey RM et al. Involvement of a calcineurin/inhibitor-1 phosphatase cascade in hippocampal long-term depression. 1994 Nature pmid:7515479
Breuder T et al. Calcineurin is essential in cyclosporin A- and FK506-sensitive yeast strains. 1994 Proc. Natl. Acad. Sci. U.S.A. pmid:7515500
Kawauchi M et al. Cardiac xenotransplantation from pig to Japanese monkey with splenectomy, tacrolims, filtration plasmapheresis, and nafamstat mesilate. 1994 Transplant. Proc. pmid:7518105
Ohtsuka S et al. Effect of splenectomy on hamster-to-rat pancreas xenotransplantation. 1994 Transplant. Proc. pmid:7518109
Yasutomi M et al. Mechanism of antibody production in hamster-to-rat concordant xenotransplantation: establishment of a simple model using intravenous injection of concordant splenocytes. 1994 Transplant. Proc. pmid:7518110
Miyazawa H et al. Mechanisms of hamster kidney graft rejection in the rat. 1994 Transplant. Proc. pmid:7518111
Nardo B et al. Pretransplant xenogeneic blood transfusion combined with FK 506 prolongs hamster-to-rat liver xenograft survival. 1994 Transplant. Proc. pmid:7518112
Pan F et al. FK 506 prolongs survival of liver but not heart mouse-to-rat vascularized xenografts. 1994 Transplant. Proc. pmid:7518113
Raymond M et al. Functional expression of P-glycoprotein in Saccharomyces cerevisiae confers cellular resistance to the immunosuppressive and antifungal agent FK520. 1994 Mol. Cell. Biol. pmid:7505392
Valdivia LA et al. Complement and target cells belong to the same species after liver xenografting: protection from hyperacute rejection. 1994 Transplant. Proc. pmid:7518123
Hayashi S et al. Synergistic effect of donor pretreatment using FK 506 in hamster-to-rat cardiac xenotransplantation. 1994 Transplant. Proc. pmid:7518126
Cunningham KW and Fink GR Calcineurin-dependent growth control in Saccharomyces cerevisiae mutants lacking PMC1, a homolog of plasma membrane Ca2+ ATPases. 1994 J. Cell Biol. pmid:7507493
Wang T et al. Specific interaction of type I receptors of the TGF-beta family with the immunophilin FKBP-12. 1994 Science pmid:7518616
Fealy MJ et al. Efficacy of rapamycin and FK 506 in prolonging rat hind limb allograft survival. 1994 Ann. Surg. pmid:7507657
Tanabe M et al. Combined immunosuppressive therapy with low dose FK506 and antimetabolites in rat allogeneic heart transplantation. 1994 Transplantation pmid:7518619
Bossard MJ et al. Catalytic and ligand binding properties of the FK506 binding protein FKBP12: effects of the single amino acid substitution of Tyr82 to Leu. 1994 Biochem. J. pmid:7507662
Tamura K et al. Interaction of tacrolimus(FK506) and its metabolites with FKBP and calcineurin. 1994 Biochem. Biophys. Res. Commun. pmid:7518678
Hooks MA Tacrolimus, a new immunosuppressant--a review of the literature. 1994 Ann Pharmacother pmid:7518710
Frizell E et al. FK506 enhances fibrogenesis in in vitro and in vivo models of liver fibrosis in rats. 1994 Gastroenterology pmid:7518783
Fujimura A and Ebihara A Administration time-dependent toxicity of a new immunosuppressive agent, tacrolimus (FK 506). 1994 Life Sci. pmid:7518886
Gottschalk AR et al. Identification of immunosuppressant-induced apoptosis in a murine B-cell line and its prevention by bcl-x but not bcl-2. 1994 Proc. Natl. Acad. Sci. U.S.A. pmid:7518929
Morphopathological findings of renal allografts under FK 506 therapy. Japanese FK 506 Study Group. 1994 Transplant. Proc. pmid:7520614
Imanishi M et al. Induction of tolerance by intrathymic injection of donor bone marrow cells in the rat: simultaneous heart and skin allograft model. 1994 Transplant. Proc. pmid:7520615
Charters AR et al. Immunochemical analysis of FK506 binding proteins in neuronal cell lines and rat brain. 1994 Biochem. Soc. Trans. pmid:7535258
Matsuura T et al. Organ-specific tolerance induced by intrathymic injection of donor bone marrow cells and FK 506 or antilymphocyte serum in rat heart transplantation. 1994 Transplant. Proc. pmid:7520616
Andoh TF et al. Enhancement of FK506 nephrotoxicity by sodium depletion in an experimental rat model. 1994 Transplantation pmid:7509514
Charters AR et al. The subcellular distribution of FK506 binding proteins in rat brain. 1994 Biochem. Soc. Trans. pmid:7535259
Ota K Living donor kidney transplantation in Japan. 1994 Transplant. Proc. pmid:7520622
Bäckman L et al. FK506 trough levels in whole blood and plasma in liver transplant recipients. Correlation with clinical events and side effects. 1994 Transplantation pmid:7509516
Hirose M and Kuroda Y Reinforcement of cyclosporin A-induced red cell destruction by superoxide. 1994 Tokushima J. Exp. Med. pmid:7535479
Takahara S et al. Monitoring of FK 506 blood levels in kidney transplant recipients. 1994 Transplant. Proc. pmid:7520623
Kitamura Y et al. Suppressive effect of FK-506, a novel immunosuppressant, against MPTP-induced dopamine depletion in the striatum of young C57BL/6 mice. 1994 J. Neuroimmunol. pmid:7509816
Sun CK et al. Intensive care after orthotopic liver transplantation. 1994 Transplant. Proc. pmid:7520627
Sato K et al. Effectiveness of triple regimen immunosuppression in canine pancreatic allotransplantation. 1994 Transplant. Proc. pmid:7520628
Thomson AW Immunosuppressive drugs and the induction of transplantation tolerance. 1994 Transpl. Immunol. pmid:7535641
Oishi M et al. Successful swine small bowel transplantation using FK506: effect on endotoxin translocation. 1994 Transplant. Proc. pmid:7520629
Tai PK et al. Potentiation of progesterone receptor-mediated transcription by the immunosuppressant FK506. 1994 Biochemistry pmid:7521210
Akita K et al. Suppression of nitric oxide production by cyclosporin A and FK506A in rat vascular smooth muscle cells. 1994 Clin. Exp. Pharmacol. Physiol. pmid:7521274
Weaver JL et al. The interaction of immunosuppressive compounds in tandem stimulated peripheral human lymphocytes. 1994 Immunopharmacol Immunotoxicol pmid:7521360
Woo J et al. FK506 inhibits the differentiation of developing thymocytes but not negative selection of T cell receptor V beta 5+ and V beta 11+ T lymphocytes in vivo. 1994 Transpl. Immunol. pmid:7521743
Kasiske BL The effects of immunosuppressive agents on plasma lipoproteins after organ transplantation. 1994 J. Lab. Clin. Med. pmid:7521894
Krentz AJ et al. Serum lipids and apolipoproteins in liver transplant recipients: a comparative study of cyclosporin A and FK 506. 1994 J. Lab. Clin. Med. pmid:7521895
Jensen C et al. Interaction between tacrolimus and erythromycin. 1994 Lancet pmid:7521928
Winkler M et al. Comparison of different assays for the quantitation of FK 506 levels in blood or plasma. 1994 Ther Drug Monit pmid:7521978
Holländer GA et al. Molecular and biological actions of cyclosporin A and FK506 on T cell development and function. 1994 Transfus Sci pmid:10155542
Karmann K et al. Endothelial cell-induced resistance to cyclosporin A in human peripheral blood T cells requires contact-dependent interactions involving CD2 but not CD28. 1994 J. Immunol. pmid:7523510
Hiromura K et al. FK506 inhibits renal glomerular thrombosis induced in rats by nephrotoxic serum and lipopolysaccharide. 1994 Kidney Int. pmid:7523750
Ohtomo Y et al. Coexisting NPY and NE synergistically regulate renal tubular Na+, K(+)-ATPase activity. 1994 Kidney Int. pmid:7523751
Siekierka JJ Probing T-cell signal transduction pathways with the immunosuppressive drugs, FK-506 and rapamycin. 1994 Immunol. Res. pmid:7539823
Moore R and Lord R Tacrolimus (FK506) versus cyclosporin in prevention of liver allograft rejection. 1994 Lancet pmid:7523805
Krentz AJ et al. Tacrolimus (FK506) versus cyclosporin in prevention of liver allograft rejection. 1994 Lancet pmid:7523806
Collins RH Tacrolimus (FK506) versus cyclosporin in prevention of liver allograft rejection. 1994 Lancet pmid:7523807
Schmidt A et al. Two FK506 resistance-conferring genes in Saccharomyces cerevisiae, TAT1 and TAT2, encode amino acid permeases mediating tyrosine and tryptophan uptake. 1994 Mol. Cell. Biol. pmid:7523855
A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. The U.S. Multicenter FK506 Liver Study Group. 1994 N. Engl. J. Med. pmid:7523946
Shafiee A et al. Enzymology of FK-506 biosynthesis. Purification and characterization of 31-O-desmethylFK-506 O:methyltransferase from Streptomyces sp. MA6858. 1994 Eur. J. Biochem. pmid:7525282
Benton BM et al. A novel FK506- and rapamycin-binding protein (FPR3 gene product) in the yeast Saccharomyces cerevisiae is a proline rotamase localized to the nucleolus. 1994 J. Cell Biol. pmid:7525596
Gruber SA et al. Pharmacokinetics of FK506 after intravenous and oral administration in patients awaiting renal transplantation. 1994 J Clin Pharmacol pmid:7525661
Funk JO and Maibach HI Horizons in pharmacologic intervention in allergic contact dermatitis. 1994 J. Am. Acad. Dermatol. pmid:7525668
Mukaida N et al. Molecular mechanism of interleukin-8 gene expression. 1994 J. Leukoc. Biol. pmid:7525815
Hiromatsu Y et al. Inhibitory effect of FK506 on intercellular adhesion molecule-1 (ICAM-1) expression on cultured thyroid cells. 1994 Kurume Med J pmid:7526029
Kinoshita I et al. Very efficient myoblast allotransplantation in mice under FK506 immunosuppression. 1994 Muscle Nerve pmid:7526208
Matsunami H et al. New technique for measuring tacrolimus concentrations in blood. 1994 Am J Hosp Pharm pmid:7510929
Renoir JM et al. Effects of immunosuppressants FK506 and rapamycin on the heterooligomeric form of the progesterone receptor. 1994 J. Steroid Biochem. Mol. Biol. pmid:7510997
Ayres RC et al. Peripheral neurotoxicity with tacrolimus. 1994 Lancet pmid:7511197
Devlin J et al. Renal complications and development of hypertension in the European study of FK 506 and cyclosporin in primary liver transplant recipients. 1994 Transpl. Int. pmid:11271207
Two-year follow-up study of the efficacy and safety of FK 506 in kidney transplant patients. Japanese FK 506 Study Group. 1994 Transpl. Int. pmid:11271216
Neuhaus P et al. Neurological complications in the European multicentre study of FK 506 and cyclosporin in primary liver transplantation. 1994 Transpl. Int. pmid:11271222
Bismuth H et al. Focus on intractable rejection: 6-month results of the European multicentre liver study of FK 506 and cyclosporin A. 1994 Transpl. Int. pmid:11271231
McMaster P Patient and graft survival in the European Multicentre Liver Study--FK 506 vs cyclosporin A. 1994 Transpl. Int. pmid:11271239
Mueller AR et al. Neurotoxicity after orthotopic liver transplantation in cyclosporin A- and FK 506-treated patients. 1994 Transpl. Int. pmid:11271254
D'Silva M et al. The immunomodulatory effects of a novel agent, leflunomide, in rat cardiac allotransplantation. 1994 Transpl. Int. pmid:11271257
Trocha K et al. Neurological examinations after liver transplantation concerning patients under corticosteroid immunosuppression and either FK 506 or cyclosporin. 1994 Transpl. Int. pmid:11271273
Nielsen FT et al. Nephrotoxity of FK 506: a preliminary study on comparative aspects of FK 506 and cyclosporine nephrotoxicity. 1994 Transplant. Proc. pmid:7527946
Fisher A et al. Gastrointestinal toxicity associated with FK 506 in liver transplant recipients. 1994 Transplant. Proc. pmid:7527947